August 13
Six Australian startup health innovators awarded $13.5 million through CUREator+ to accelerate breakthrough medical therapies and technologies.
Read moreBrandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areA clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapy
View ProjectDeveloping disease-modifying mitochondrial therapeutics for neurodegenerative disorders
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectUnlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View ProjectThe Ferrier Research Institute, Victoria University of Wellington, New Zealand is named after the late Professor Robin Ferrier who pioneered carbohydrate chemistry in New Zealand.
ViewMater Research is a recognised leader in medical research. Our bench to bedside philosophy sees us working across Mater Health’s hospitals and health services, The University of Queensland, and the world-class Translational Research Institute (TRI).
ViewPeter Mac is one of the world’s leading cancer research, education and treatment centres globally and is Australia’s only public hospital solely dedicated to caring for people affected by cancer. There are over 2,500 staff, including more than 600 laboratory and clinical researchers, all focused on providing better treatments, better care and potential cures for cancer.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreSix Australian startup health innovators awarded $13.5 million through CUREator+ to accelerate breakthrough medical therapies and technologies.
Read moreKraken Coding: from hospital pharmacy to health-tech founder on a mission to help clinicians make faster, safer decisions
Read more